CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- 4 Grant or award SVP, Chief Marketing Officer acquired 125,000 shares (grant or award)
- 4 Grant or award SVP, Business Development acquired 125,000 shares (grant or award)
- 4 Grant or award SVP & General Counsel acquired 125,000 shares (grant or award)
- 4 Grant or award SVP, CFO & Treasurer acquired 125,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 525,000 shares (grant or award)
- 4 Open-market buy President and CEO bought 10,000 shares at $4.15 ($41,500)
- 4 Open-market sale Director sold 7,000 shares at $4.59 ($32,130)
- 4 Grant or award Director acquired 59,225 shares (grant or award)
- 4 Grant or award Director acquired 59,225 shares (grant or award)
- 4 Grant or award Director acquired 59,225 shares (grant or award)
- 4 Grant or award Director acquired 59,225 shares (grant or award)
- 4 Grant or award Director acquired 59,225 shares (grant or award)
- 4 Open-market buy President and CEO bought 10,000 shares at an average $4.40 ($43,995)
- 4 Open-market buy President and CEO bought 20,000 shares at $4.22 ($84,472)
- 4 Open-market buy President and CEO bought 10,000 shares at an average $5.02 ($50,150)
- 4 Open-market buy President and CEO bought 10,000 shares at an average $5.02 ($50,200)
- 4 Shares withheld for taxes SVP, Chief Marketing Officer gave up 15,520 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Business Development gave up 26,941 shares (to pay taxes)
- 4 Open-market buy President and CEO bought 10,000 shares at $4.71 ($47,050)
- 4 Shares withheld for taxes SVP, CFO & Treasurer gave up 26,941 shares (to pay taxes)
Page 2 of 29 · 579 filings